IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Checkpoint/cancer vaccines represent a novel approach inducing or activating anti Tregs that is highly synergistic with any other immune-oncology therapeutic approaches. Anti Tregs target the regulatory cells - not immune checkpoint receptors targeted by e.g. antibodies. Thus, by killing the immuno-supressive cells anti Tregs remove immune suppression allowing for intratumoral inflammation and subsequent elimination of cancer cells.
IO Biotech has already shown clinical validation of an IDO vaccine in a clinical phase I trial in a small number of patients with non-small cell lung cancer (NSCLC) (Iversen et al., Clinical Cancer Research, 2014 Jan 1;20(1):221-32).
Vaccine-treated patients had significantly increased overall survival compared to non-vaccine-treated patients, and tumor regression was observed in one patient with liver metastasis.